{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:09:41Z","timestamp":1740107381851,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00417-024-06492-z","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T08:02:12Z","timestamp":1714118532000},"page":"3135-3142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema"],"prefix":"10.1007","volume":"262","author":[{"given":"Ys\u00e9","family":"Borella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Bertaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Tadayoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Dupas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8346-3067","authenticated-orcid":false,"given":"Sara","family":"Touhami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"6492_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/08820539909069541","volume":"14","author":"RJ Antcliff","year":"1999","unstructured":"Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223\u2013232. https:\/\/doi.org\/10.3109\/08820539909069541","journal-title":"Semin Ophthalmol"},{"key":"6492_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ajo.2018.07.030","volume":"195","author":"NM Bressler","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Maguire MG et al (2018) Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes with Diabetic Macular Edema in Protocol T. Am J Ophthalmol 195:93\u2013100. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.030","journal-title":"Am J Ophthalmol"},{"key":"6492_CR3","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.3390\/ijms23147585","volume":"23","author":"MR Munk","year":"2022","unstructured":"Munk MR, Somfai GM, de Smet MD et al (2022) The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Int J Mol Sci 23:7585. https:\/\/doi.org\/10.3390\/ijms23147585","journal-title":"Int J Mol Sci"},{"key":"6492_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00592-019-01424-4","volume":"57","author":"S Vujosevic","year":"2020","unstructured":"Vujosevic S, Toma C, Villani E et al (2020) Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol 57:287\u2013296. https:\/\/doi.org\/10.1007\/s00592-019-01424-4","journal-title":"Acta Diabetol"},{"key":"6492_CR5","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/cells11213362","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang J, Zhang C et al (2022) Diabetic Macular Edema: Current Understanding. Mol Mech Therapeutic Implications Cells 11:3362. https:\/\/doi.org\/10.3390\/cells11213362","journal-title":"Mol Mech Therapeutic Implications Cells"},{"key":"6492_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","volume":"136","author":"RK Maturi","year":"2018","unstructured":"Maturi RK, Glassman AR, Liu D et al (2018) Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol 136:29\u201338. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4914","journal-title":"JAMA Ophthalmol"},{"key":"6492_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12886-018-1022-9","volume":"19","author":"V Castro-Navarro","year":"2019","unstructured":"Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C et al (2019) Intravitreal dexamethasone implant Ozurdex\u00ae in na\u00efve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol 19:15. https:\/\/doi.org\/10.1186\/s12886-018-1022-9","journal-title":"BMC Ophthalmol"},{"key":"6492_CR8","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904\u20131914. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.024","journal-title":"Ophthalmology"},{"key":"6492_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.oret.2022.10.008","volume":"7","author":"NS Patil","year":"2023","unstructured":"Patil NS, Mihalache A, Hatamnejad A et al (2023) Intravitreal Steroids Compared with Anti-VEGF Treatment for Diabetic Macular Edema: A Meta-Analysis. Ophthalmol Retina 7:289\u2013299. https:\/\/doi.org\/10.1016\/j.oret.2022.10.008","journal-title":"Ophthalmol Retina"},{"key":"6492_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa2204225","volume":"387","author":"CD Jhaveri","year":"2022","unstructured":"Jhaveri CD, Glassman AR, Ferris FL et al (2022) Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med 387:692\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa2204225","journal-title":"N Engl J Med"},{"key":"6492_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/09273948.2019.1620786","volume":"27","author":"B Erden","year":"2019","unstructured":"Erden B, \u00c7ak\u0131r A, Aslan AC et al (2019) The Efficacy of Posterior Subtenon Triamcinolone Acetonide Injection in Treatment of Irvine-Gass Syndrome. Ocul Immunol Inflamm 27:1235\u20131241. https:\/\/doi.org\/10.1080\/09273948.2019.1620786","journal-title":"Ocul Immunol Inflamm"},{"key":"6492_CR12","doi-asserted-by":"publisher","first-page":"16471","DOI":"10.1038\/s41598-022-20522-y","volume":"12","author":"P Choopong","year":"2022","unstructured":"Choopong P, Taetrongchit N, Boonsopon S et al (2022) Efficacy of subtenon 20-mg triamcinolone injection versus 0.1% dexamethasone eye drops for controlling inflammation after phacoemulsification: a randomized controlled trial. Sci Rep 12:16471. https:\/\/doi.org\/10.1038\/s41598-022-20522-y","journal-title":"Sci Rep"},{"key":"6492_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/jop.2014.0130","volume":"31","author":"YB Ozkurt","year":"2015","unstructured":"Ozkurt YB, Akkaya S, Aksoy S et al (2015) Posterior Subtenon\u2019s Capsule Triamcinolone Acetonide Injection for the Treatment of Diabetic Macular Edema. J Ocul Pharmacol Ther 31:455\u2013460. https:\/\/doi.org\/10.1089\/jop.2014.0130","journal-title":"J Ocul Pharmacol Ther"},{"key":"6492_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40123-022-00480-4","volume":"11","author":"JL Jung","year":"2022","unstructured":"Jung JL, Harasawa M, Patnaik JL, Palestine AG (2022) Subtenon Triamcinolone Acetonide Injection with Topical Anesthesia in Pediatric Non-Infectious Uveitis. Ophthalmol Ther 11:811\u2013820. https:\/\/doi.org\/10.1007\/s40123-022-00480-4","journal-title":"Ophthalmol Ther"},{"key":"6492_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/ijo.IJO_621_22","volume":"71","author":"G Erdogan","year":"2023","unstructured":"Erdogan G, Gumus G, Gunay BO, Ozkaya A (2023) Posterior sub-Tenon triamcinolone injection in the treatment of postoperative cystoid macular edema secondary to pars plana vitrectomy. Indian J Ophthalmol 71:174\u2013179. https:\/\/doi.org\/10.4103\/ijo.IJO_621_22","journal-title":"Indian J Ophthalmol"},{"key":"6492_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jfo.2016.11.013","volume":"40","author":"C Carbonni\u00e8re","year":"2017","unstructured":"Carbonni\u00e8re C, Couret C, Bl\u00e9riot A et al (2017) Treatment of macular edema: Comparison of efficacy and tolerability of subconjunctival triamcinolone injections, sub-tenon\u2019s triamcinolone injections and intravitreal dexamethasone implant. J Fr Ophtalmol 40:177\u2013186. https:\/\/doi.org\/10.1016\/j.jfo.2016.11.013","journal-title":"J Fr Ophtalmol"},{"key":"6492_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","volume":"126","author":"JE Thorne","year":"2019","unstructured":"Thorne JE, Sugar EA, Holbrook JT et al (2019) Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 126:283\u2013295. https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.021","journal-title":"Ophthalmology"},{"key":"6492_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000526172","volume":"245","author":"G Gumus","year":"2022","unstructured":"Gumus G, Erdogan G, Gunay BO, Karatas Durusoy G (2022) Comparison of Intravitreal Dexamethasone Implant and Posterior Subtenon Triamcinolone Injection in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes. Ophthalmologica 245:439\u2013445. https:\/\/doi.org\/10.1159\/000526172","journal-title":"Ophthalmologica"},{"key":"6492_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12886-018-0779-1","volume":"18","author":"Y He","year":"2018","unstructured":"He Y, Ren X-J, Hu B-J et al (2018) A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol 18:121. https:\/\/doi.org\/10.1186\/s12886-018-0779-1","journal-title":"BMC Ophthalmol"},{"key":"6492_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ophtha.2021.07.009","volume":"129","author":"JP Ehlers","year":"2022","unstructured":"Ehlers JP, Yeh S, Maguire MG et al (2022) Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology 129:88\u201399. https:\/\/doi.org\/10.1016\/j.ophtha.2021.07.009","journal-title":"Ophthalmology"},{"key":"6492_CR21","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1177\/11206721211024804","volume":"32","author":"AV Bux","year":"2022","unstructured":"Bux AV, Fortunato F, Barone A et al (2022) Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Na\u00efve versus refractory patients. Eur J Ophthalmol 32:1619\u20131626. https:\/\/doi.org\/10.1177\/11206721211024804","journal-title":"Eur J Ophthalmol"},{"key":"6492_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00417-016-3472-1","volume":"255","author":"DG Callanan","year":"2017","unstructured":"Callanan DG, Loewenstein A, Patel SS et al (2017) A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255:463\u2013473. https:\/\/doi.org\/10.1007\/s00417-016-3472-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6492_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2415-8-5","volume":"8","author":"M Cellini","year":"2008","unstructured":"Cellini M, Pazzaglia A, Zamparini E et al (2008) Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmol 8:5. https:\/\/doi.org\/10.1186\/1471-2415-8-5","journal-title":"BMC Ophthalmol"},{"key":"6492_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3341\/kjo.2006.20.4.205","volume":"20","author":"YJ Choi","year":"2006","unstructured":"Choi YJ, Oh IK, Oh JR, Huh K (2006) Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean J Ophthalmol 20:205\u2013209. https:\/\/doi.org\/10.3341\/kjo.2006.20.4.205","journal-title":"Korean J Ophthalmol"},{"key":"6492_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/eye.2017.46","volume":"31","author":"MM Kurt","year":"2017","unstructured":"Kurt MM, \u00c7eki\u00e7 O, Akpolat \u00c7 et al (2017) Vessel diameter study: intravitreal vs posterior subtenon triamcinolone acetonide injection for diabetic macular edema. Eye (Lond) 31:1155\u20131162. https:\/\/doi.org\/10.1038\/eye.2017.46","journal-title":"Eye (Lond)"},{"key":"6492_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ajo.2004.09.038","volume":"139","author":"SJ Bakri","year":"2005","unstructured":"Bakri SJ, Kaiser PK (2005) Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 139:290\u2013294. https:\/\/doi.org\/10.1016\/j.ajo.2004.09.038","journal-title":"Am J Ophthalmol"},{"key":"6492_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3341\/kjo.2016.30.1.25","volume":"30","author":"MW Kim","year":"2016","unstructured":"Kim MW, Moon H, Yang SJ, Joe SG (2016) Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection. Korean J Ophthalmol 30:25\u201331. https:\/\/doi.org\/10.3341\/kjo.2016.30.1.25","journal-title":"Korean J Ophthalmol"},{"key":"6492_CR28","doi-asserted-by":"publisher","first-page":"6882607","DOI":"10.1155\/2022\/6882607","volume":"2022","author":"B Liu","year":"2022","unstructured":"Liu B, Ma G, Hou J, Cong C (2022) Choroidal Structural Changes of Posterior Subtenon Triamcinolone Acetonide Injection in Eyes with Refractory Diabetic Macular Edema. J Ophthalmol 2022:6882607. https:\/\/doi.org\/10.1155\/2022\/6882607","journal-title":"J Ophthalmol"},{"key":"6492_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10384-016-0458-9","volume":"60","author":"M Shimura","year":"2016","unstructured":"Shimura M, Yasuda K, Minezaki T, Noma H (2016) Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema. Jpn J Ophthalmol 60:401\u2013407. https:\/\/doi.org\/10.1007\/s10384-016-0458-9","journal-title":"Jpn J Ophthalmol"},{"key":"6492_CR30","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ajo.2004.05.028","volume":"138","author":"M Inoue","year":"2004","unstructured":"Inoue M, Takeda K, Morita K et al (2004) Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 138:1046\u20131048. https:\/\/doi.org\/10.1016\/j.ajo.2004.05.028","journal-title":"Am J Ophthalmol"},{"key":"6492_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000492135","volume":"241","author":"Y Ogura","year":"2019","unstructured":"Ogura Y, Shimura M, Iida T et al (2019) Phase II\/III Clinical Trial of Sub-Tenon Injection of Triamcinolone Acetonide (WP-0508ST) for Diabetic Macular Edema. Ophthalmologica 241:161\u2013169. https:\/\/doi.org\/10.1159\/000492135","journal-title":"Ophthalmologica"},{"key":"6492_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ophtha.2019.10.005","volume":"127","author":"A Rosenblatt","year":"2020","unstructured":"Rosenblatt A, Udaondo P, Cunha-Vaz J et al (2020) A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study. Ophthalmology 127:377\u2013393. https:\/\/doi.org\/10.1016\/j.ophtha.2019.10.005","journal-title":"Ophthalmology"},{"key":"6492_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.17925\/EE.2014.10.02.111","volume":"10","author":"M Dutra Medeiros","year":"2014","unstructured":"Dutra Medeiros M, Alkabes M, Nucci P (2014) Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema. Eur Endocrinol 10:111\u2013116. https:\/\/doi.org\/10.17925\/EE.2014.10.02.111","journal-title":"Eur Endocrinol"},{"key":"6492_CR34","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.18240\/ijo.2020.10.13","volume":"13","author":"H-H Xia","year":"2020","unstructured":"Xia H-H, Chen J-L, Chen H-Y, Lin H-J (2020) Correlation between optical coherence tomography, multifocal electroretinogram findings and visual acuity in diabetic macular edema. Int J Ophthalmol 13:1592\u20131596. https:\/\/doi.org\/10.18240\/ijo.2020.10.13","journal-title":"Int J Ophthalmol"},{"key":"6492_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3109\/02713683.2015.1019003","volume":"41","author":"Y Shen","year":"2016","unstructured":"Shen Y, Liu K, Xu X (2016) Correlation Between Visual Function and Photoreceptor Integrity in Diabetic Macular Edema: Spectral-Domain Optical Coherence Tomography. Curr Eye Res 41:391\u2013399. https:\/\/doi.org\/10.3109\/02713683.2015.1019003","journal-title":"Curr Eye Res"},{"key":"6492_CR36","doi-asserted-by":"publisher","first-page":"8216150","DOI":"10.1155\/2019\/8216150","volume":"2019","author":"AH Abd Elhamid","year":"2019","unstructured":"Abd Elhamid AH (2019) Quantitative Assessment of Outer Retinal Layer and Photoreceptor Outer Segment Layer and Their Relation to Visual Acuity in Diabetic Macular Edema. J Ophthalmol 2019:8216150. https:\/\/doi.org\/10.1155\/2019\/8216150","journal-title":"J Ophthalmol"},{"key":"6492_CR37","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/j.diabres.2008.10.020","volume":"84","author":"J Toda","year":"2009","unstructured":"Toda J, Fukushima H, Kato S (2009) Systemic complications of posterior subtenon injection of triamcinolone acetonide in type 2 diabetes patients. Diabetes Res Clin Pract 84:e38-40. https:\/\/doi.org\/10.1016\/j.diabres.2008.10.020","journal-title":"Diabetes Res Clin Pract"},{"key":"6492_CR38","first-page":"2609","volume":"18","author":"B Kaderli","year":"2014","unstructured":"Kaderli B, Kivanc SA, Inan UU et al (2014) Effect of posterior subtenon injection of 40 mg of triamcinolone acetonide on glycemic control and serum cortisol and adrenocorticotropic hormone in diabetic patients. Eur Rev Med Pharmacol Sci 18:2609\u20132614","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"6492_CR39","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4239\/wjd.v12.i8.1220","volume":"12","author":"O Karti","year":"2021","unstructured":"Karti O, Saatci AO (2021) Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema. World J Diabetes 12:1220\u20131232. https:\/\/doi.org\/10.4239\/wjd.v12.i8.1220","journal-title":"World J Diabetes"},{"key":"6492_CR40","doi-asserted-by":"publisher","first-page":"CD01599","DOI":"10.1002\/14651858.CD011599.pub2","volume":"4","author":"H Mehta","year":"2018","unstructured":"Mehta H, Hennings C, Gillies MC et al (2018) Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev 4:CD01599. https:\/\/doi.org\/10.1002\/14651858.CD011599.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"6492_CR41","doi-asserted-by":"publisher","first-page":"946","DOI":"10.18240\/ijo.2020.06.14","volume":"13","author":"Y-H Yang","year":"2020","unstructured":"Yang Y-H, Kuo H-H, Hsu W-C, Hsieh Y-T (2020) Ocular hypertension and severe intraocular pressure elevation after posterior subtenon injection of triamcinolone acetonide for various diseases. Int J Ophthalmol 13:946\u2013951. https:\/\/doi.org\/10.18240\/ijo.2020.06.14","journal-title":"Int J Ophthalmol"},{"key":"6492_CR42","unstructured":"Base de donn\u00e9es publique des m\u00e9dicaments. https:\/\/base-donnees-publique.medicaments.gouv.fr\/"},{"key":"6492_CR43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4103\/ijo.IJO_1963_22","volume":"71","author":"K Tripathy","year":"2023","unstructured":"Tripathy K (2023) Commentary: Posterior subtenon triamcinolone - The unsung hero for managing various ocular disorders. Indian J Ophthalmol 71:181\u2013182. https:\/\/doi.org\/10.4103\/ijo.IJO_1963_22","journal-title":"Indian J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06492-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06492-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06492-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T03:37:58Z","timestamp":1728358678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06492-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6492"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06492-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"14 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Ophtalmologie, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Fully informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"RT, BB, BD and ST received travel grants and consultant fees from Allergan\/Abbvie, Novartis and Bayer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}